ClinicalTrials.gg
TerminatedNCT01374087ANABRAQUpdated Sep 18, 2019Results posted

Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate Cancer

A Phase 2 interventional study of Triptorelin 22.5 mg and Brachytherapy in Prostate Cancer, sponsored by Ipsen. Terminated at 11 sites in Spain. Open to male participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-09-18.

Sponsored by Ipsen · Phase 2, Interventional, and Treatment

Why this study was terminated
Slow enrollment of patients.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing triptorelin in Prostatic Neoplasms — 6 open to participants now, 6 under way, 3 of them phase 3. triptorelin · Prostatic Neoplasms.

Enrollment
23rd of 28
32 · median 120
Started
2011
the only one that year
Phase 2
7 of 28
3 open now
Registered
10th of 28
by date
Lead sponsor
9 of 28
Ipsen

Among the 28 studies testing triptorelin in Prostatic Neoplasms, this one is the 23rd largest by enrollment, is the only one that started in 2011, is one of 7 in phase 2, and was the 10th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

6 of the 28 studies testing triptorelin in Prostatic Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About triptorelin

triptorelin: first FDA approval 2000 (TRELSTAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years to 75 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing triptorelin in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The primary objective of the study was to compare the efficacy of brachytherapy versus brachytherapy + triptorelin 22.5 mg (single injection) in subjects with recurrence of prostate cancer previously treated with radiotherapy. Efficacy was to be assessed by biochemical failure-free survival (BFFS) curves from treatment initiation up to 5 years.

Secondary objectives included comparing the following: the differences in time to progression of subjects receiving brachytherapy + triptorelin 22.5 mg versus subjects receiving brachytherapy only, the BFFS percentages between both treatment groups at 5 years from treatment initiation, overall survival between both treatment groups, total testosterone changes (from baseline visit up to 12 months) and Prostate Specific Antigen (PSA) levels (from baseline visit up to 60 months of treatment) between both treatment groups, quality of life (QoL) modifications (Spanish version of the Expanded Prostate Cancer Index Composite (EPIC) questionnaire) between the baseline score and the rest of measurements, and to compare safety between both treatment groups.

Read the detailed description

This was a proof-of-concept, prospective, parallel, multicentre, randomised and open-label trial, including a follow-up of all subjects conducted at 11 centres in Spain. Study visits included an inclusion visit (Visit 1), a treatment administration visit (Visit 2), and 9 follow-up visits (Visit 3 to Visit 11) from 3 to 60 months after study treatment administration. All of the procedures performed at these visits were in accordance with routine clinical practice. Subjects were randomised to any one of the two treatment arms (Group 1: brachytherapy only, or Group 2: brachytherapy + triptorelin 22.5 mg). Randomisation was stratified according to the brachytherapy dose rate (low or high dose rate).

Visit 1 included the collection of demographic data, a review of clinical details of prostate cancer and its treatment, blood sampling (for Prostate Specific Antigen (PSA), testosterone, and haematology and biochemistry parameters, as appropriate), administration of the QoL questionnaire and International Prostatic Symptom Score (IPSS), and treatment group allocation. Visit 2 included a review of the eligibility criteria, recording of concomitant medications and adverse events (AEs) and study drug administration. Visits 3 to 11 included recording of AEs and concomitant medications, blood sampling and administration of the QoL questionnaire and IPSS.

Following the selection visit (Visit 1), all subjects were scheduled to brachytherapy. Those subjects who were randomised to the concomitant hormone therapy group received a single dose of triptorelin 22.5 mg by intramuscular injection at Visit 2, 2 weeks following the selection visit (Visit 1), and preferably 2 months before receiving brachytherapy. One week before and two weeks after triptorelin administration, subjects were permitted to receive an anti-androgen to counteract a transient increase in testosterone levels.

The study was prematurely stopped due to the slow enrolment of subjects. Of the planned 86 evaluable subjects, 35 were screened, and 32 were randomised between 3 November 2011 and 26 May 2014. The slow inclusion of subjects was due to several factors, among which there were changes in clinical practice which caused such subjects to be offered alternative treatments to brachytherapy. Due to the small number of subjects, none of the planned efficacy analyses were performed. Instead, the data were analysed as follows:

  • Efficacy data and quality of life (QoL) outcomes were displayed only in listings.
  • Safety information was displayed using listings and summary tables.
03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Recurrent Prostate Carcinoma
  • Brachytherapy
  • Triptorelin
  • Hormone Therapy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. A history of prostate cancer (T1-T2-T3 N0 M0), confirmed through histopathology and initially treated with radiotherapy.
  2. Age ≤ 75 years.
  3. Biochemical failure due to Phoenix criteria (nadir + 2) and local recurrence of the initial prostate cancer, confirmed by prostate , with neither regional involvement nor distant .
  4. Late local recurrence of the initial prostate cancer. A recurrence is late when it appears after longer than 18 months post-radiotherapy.
  5. PSA \< 10 ng/mL at the time of recurrence.
  6. The subject was required to be amenable to brachytherapy treatment.
  7. Adequate urinary function according to the questionnaire (IPSS ≤ 20 points).
  8. Suitable bone marrow function, determined by:

    • > 10 g/dL.
    • > 1.5 x 10\^9/L.
    • count > 100 x 10\^9/L.
  9. Suitable liver function determined by: serum \< 1.5 x Upper Normal Level (UNL), and (ALT) or aspartate aminotransferase (AST) \< 2.5xUNL.
  10. Suitable renal function determined by: serum creatinine \< 1.5 x UNL, or ≥ 60 mL/min.
  11. The subject was required to be ≥ 18 years old.
  12. The subject had to give his written (personally signed and dated) before starting with any study-related procedure.
  13. > 5 years.

Exclusion criteria

Exclusion Criteria:

  1. Evidence of disease.
  2. Previous evidence of hormone-resistant cancer.
  3. Lack of availability for performing regular follow-up.
  4. Subjects who were receiving or had received either luteinizing hormone-releasing hormone (LH-RH) agonists, or antagonists, over the previous 12 months.
  5. Subjects who had been on treatment with other hormone therapies, including antagonists, megestrol acetate, finasteride, dutasteride, any herbaceous product known to reduce the PSA levels, or any systemic , over the previous 4 weeks.
  6. Subjects who had previously undergone a radiotherapy treatment that was completed within 18 months of inclusion.
  7. Subjects with pre-existing heart failure ( class III or IV), or with a myocardial infarction within 6 months of inclusion.
  8. Subjects with a significant co-existing disease or an active infection.
  9. Subjects who had been treated with therapies within 4 weeks prior to the brachytherapy ± triptorelin treatment.
  10. Subjects with known to triptorelin, LH-RH, other LH-RH-analogous agonists, or any in triptorelin 22.5 mg.
  11. Subjects with a mental condition that prevented them from understanding the nature, the scope and the potential consequences of this study, and/or subjects who showed an uncooperative attitude.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Brachytherapy + Triptorelin 22.5 mg

    Brachytherapy: Low or high dose rate. Triptorelin: A single, intramuscular injection (22.5 mg), preferably 2 months before brachytherapy.

    Drug: Triptorelin 22.5 mg · Radiation: Brachytherapy

  • Active comparator
    Brachytherapy

    Brachytherapy: Low or high dose rate.

    Radiation: Brachytherapy

Interventions

  • Triptorelin: A single, intramuscular injection (22.5 mg), preferably 2 months before brachytherapy.

  • RadiationBrachytherapy

    Brachytherapy: Low or high dose rate.

06

What researchers measure

Primary outcomes

  1. Biochemical Failure-free Survival (BFFS)

    BFFS was determined by a prostate-specific antigen (PSA) increase of 2 nanograms per millilitre (ng/mL) or more in comparison with the pre-study nadir PSA and confirmed in the course of follow-up by a second value 3 weeks later or longer over the 5 year follow-up. Time to BFFS was defined from treatment initiation to the first time when PSA increase of 2 ng/mL was observed. As the study was prematurely terminated, no analyses were conducted. Data for BFFS are listed by subject for those individuals who reported biochemical failure. Time (in months) to biochemical failure is relative to the date of brachytherapy.

    Time frame: Up to 5 years

Secondary outcomes

  1. Time to Progression

    Time to progression (in months) was measured from the informed consent date to the date of first event occurrence. Progression was defined as either: death from all causes or disease progression (defined as PSA increased by 2 ng/mL as compared to the pre-trial nadir PSA, confirmed during follow-up by a second value after 3 or more weeks, or the diagnosis of a new clinical recurrence of their prostate cancer (metastasis, new injury, etc.)). As the study was prematurely terminated, no analyses were conducted. Data for time to progression are listed by subject for those individuals who reported progression.

    Time frame: Up to 5 years

  2. BFFS Percentage 5 Years From Treatment Initiation

    A subject had a biochemical failure if there was an increase of PSA of 2 ng/mL or more in comparison with the pre-study nadir PSA confirmed in the course of follow-up by a second value after 3 or more weeks or with diagnosis of a new clinical recurrence of their prostate cancer over the 5 year follow-up.

    Time frame: 5 years

  3. Overall Survival

    Overall survival was defined as the time in months from diagnosis (biopsy date for local recurrence) to death due to any cause, the last visit or the loss to follow-up.

    Time frame: 5 years

  4. Number of Participants With Change in Total Serum Testosterone Levels From Baseline at 3, 6 and 12 Months

    Blood samples were drawn for serum testosterone at baseline (Visit 1) and then at 3, 6 and 12 months. Changes from baseline in total serum testosterone levels in relation to the normal parameter ranges are indicated. WNR = Within Normal Range, BNR= Below Normal Range and ANR = Above Normal Range.

    Time frame: Baseline and 3, 6 and 12 months

  5. Number of Participants With Change in Total Serum PSA Levels From Baseline at 3, 6 and 12 Months

    Blood samples were drawn for serum PSA at baseline (Visit 1) and at 3, 6 and 12 months. Changes from baseline in total serum PSA levels in relation to the normal parameter ranges are indicated. WNR = Within Normal Range, BNR= Below Normal Range and ANR = Above Normal Range.

    Time frame: Baseline and 3, 6 and 12 months

  6. Change in Quality of Life (QoL) Modifications (Spanish Version of the Expanded Prostate Cancer Index Composite (EPIC) Questionnaire) From Baseline at 5 Years

    EPIC assessed the disease-specific aspects of prostate cancer and its therapies and comprised four summary domains (Urinary, Bowel, Sexual and Hormonal). Factor analysis supported dividing the Urinary Domain Summary Score into two different Incontinence and Irritative/Obstructive subscales. In addition, each Domain Summary Score had measurable Function Subscale and Bother Subscale components. Response options for each EPIC item formed a Likert scale, and multi-item scale scores were transformed linearly to a 0-100 scale, with higher scores representing better Health-Related QoL.

    Time frame: Baseline and 5 years.

07

Results

Posted Feb 23, 2017
Limitations and caveats
The study was prematurely stopped due to slow enrolment and all subjects were withdrawn following study termination in December 2014. Due to the small number of participating subjects very limited analyses were performed for the efficacy endpoints.

Participant flow

Subjects with recurrence of prostate cancer previously treated with radiotherapy were recruited in 11 sites in Spain from November 2011 until December 2014 when the study was prematurely discontinued.

Participant flow — Overall Study
MilestoneBrachytherapyBrachytherapy + Triptorelin 22.5 mg
Started1615
Completed00
Not completed1615
Withdrew: Adverse event10
Withdrew: Disease progression22
Withdrew: Study discontinued1313

Outcome measures

PrimaryBiochemical Failure-free Survival (BFFS)

BFFS was determined by a prostate-specific antigen (PSA) increase of 2 nanograms per millilitre (ng/mL) or more in comparison with the pre-study nadir PSA and confirmed in the course of follow-up by a second value 3 weeks later or longer over the 5 year follow-up. Time to BFFS was defined from treatment initiation to the first time when PSA increase of 2 ng/mL was observed. As the study was prematurely terminated, no analyses were conducted. Data for BFFS are listed by subject for those individuals who reported biochemical failure. Time (in months) to biochemical failure is relative to the date of brachytherapy.

Time frame:
Up to 5 years
Reported as:
Number · Months
Biochemical Failure-free Survival (BFFS)
MonthsBrachytherapyBrachytherapy + Triptorelin 22.5 mg
Subject 15.2NA
Subject 212.2NA
Subject 35.7NA
Subject 4NA24.7
Subject 5NA29.9
Subject 6NA5.6
SecondaryTime to Progression

Time to progression (in months) was measured from the informed consent date to the date of first event occurrence. Progression was defined as either: death from all causes or disease progression (defined as PSA increased by 2 ng/mL as compared to the pre-trial nadir PSA, confirmed during follow-up by a second value after 3 or more weeks, or the diagnosis of a new clinical recurrence of their prostate cancer (metastasis, new injury, etc.)). As the study was prematurely terminated, no analyses were conducted. Data for time to progression are listed by subject for those individuals who reported progression.

Time frame:
Up to 5 years
Reported as:
Number · Months
Time to Progression
MonthsBrachytherapyBrachytherapy + Triptorelin 22.5 mg
Subject 16.7NA
Subject 212.6NA
Subject 36.5NA
Subject 4NA27.2
Subject 5NA30.8
Subject 6NA16.8
Subject 7NA12.8
SecondaryBFFS Percentage 5 Years From Treatment Initiation

A subject had a biochemical failure if there was an increase of PSA of 2 ng/mL or more in comparison with the pre-study nadir PSA confirmed in the course of follow-up by a second value after 3 or more weeks or with diagnosis of a new clinical recurrence of their prostate cancer over the 5 year follow-up.

Time frame:
5 years

No measurements were reported for this outcome.

SecondaryOverall Survival

Overall survival was defined as the time in months from diagnosis (biopsy date for local recurrence) to death due to any cause, the last visit or the loss to follow-up.

Time frame:
5 years

No measurements were reported for this outcome.

SecondaryNumber of Participants With Change in Total Serum Testosterone Levels From Baseline at 3, 6 and 12 Months

Blood samples were drawn for serum testosterone at baseline (Visit 1) and then at 3, 6 and 12 months. Changes from baseline in total serum testosterone levels in relation to the normal parameter ranges are indicated. WNR = Within Normal Range, BNR= Below Normal Range and ANR = Above Normal Range.

Time frame:
Baseline and 3, 6 and 12 months
Reported as:
Count of participants · Participants
Number of Participants With Change in Total Serum Testosterone Levels From Baseline at 3, 6 and 12 Months
ParticipantsBrachytherapyBrachytherapy + Triptorelin 22.5 mg
WNR at Baseline and Month 360
WNR at Baseline, BNR at Month 317
BNR at Baseline and Month 302
WNR at Baseline and Month 652
WNR at Baseline, BNR at Month 615
BNR at Baseline and Month 602
WNR at Baseline and Month 1234
WNR at Baseline, BNR at Month 1232
BNR at Baseline and Month 1201
SecondaryNumber of Participants With Change in Total Serum PSA Levels From Baseline at 3, 6 and 12 Months

Blood samples were drawn for serum PSA at baseline (Visit 1) and at 3, 6 and 12 months. Changes from baseline in total serum PSA levels in relation to the normal parameter ranges are indicated. WNR = Within Normal Range, BNR= Below Normal Range and ANR = Above Normal Range.

Time frame:
Baseline and 3, 6 and 12 months
Reported as:
Count of participants · Participants
Number of Participants With Change in Total Serum PSA Levels From Baseline at 3, 6 and 12 Months
ParticipantsBrachytherapyBrachytherapy + Triptorelin 22.5 mg
WNR at Baseline and Month 332
ANR at Baseline and Month 320
ANR at Baseline, WNR at Month 375
WNR at Baseline and Month 625
WNR at Baseline, BNR at Month 601
ANR at Baseline and Month 630
ANR at Baseline and WNR at Month 663
WNR at Baseline and Month 1214
WNR at Baseline, BNR at Month 1201
ANR at Baseline and Month 1210
ANR at Baseline, WNR at Month 1243
SecondaryChange in Quality of Life (QoL) Modifications (Spanish Version of the Expanded Prostate Cancer Index Composite (EPIC) Questionnaire) From Baseline at 5 Years

EPIC assessed the disease-specific aspects of prostate cancer and its therapies and comprised four summary domains (Urinary, Bowel, Sexual and Hormonal). Factor analysis supported dividing the Urinary Domain Summary Score into two different Incontinence and Irritative/Obstructive subscales. In addition, each Domain Summary Score had measurable Function Subscale and Bother Subscale components. Response options for each EPIC item formed a Likert scale, and multi-item scale scores were transformed linearly to a 0-100 scale, with higher scores representing better Health-Related QoL.

Time frame:
Baseline and 5 years.

No measurements were reported for this outcome.

Adverse events

Collected over Treatment emergent adverse events were collected from treatment initiation (Day 1) to end of the study (up to 5 years).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brachytherapy—3/16 (18.8%)11/16 (68.8%)
Brachytherapy + Triptorelin 22.5 mg—2/15 (13.3%)10/15 (66.7%)
Most frequent serious events
Most frequent serious events
EventBrachytherapyBrachytherapy + Triptorelin 22.5 mg
Liver abscessInfections and infestations0/161/15
PneumoniaInfections and infestations0/161/15
Myocardial infarctionCardiac disorders1/160/15
Necrotising fasciitisInfections and infestations1/160/15
OrchitisInfections and infestations1/160/15
Scrotal abscessInfections and infestations1/160/15
HaematuriaRenal and urinary disorders1/160/15
Most frequent other events
Showing 10 of 35
Most frequent other events
EventBrachytherapyBrachytherapy + Triptorelin 22.5 mg
DysuriaRenal and urinary disorders3/164/15
HaematuriaRenal and urinary disorders2/163/15
Urinary retentionRenal and urinary disorders3/160/15
Back painMusculoskeletal and connective tissue disorders2/160/15
Hypertonic bladderRenal and urinary disorders2/161/15
Urinary incontinenceRenal and urinary disorders2/161/15
Anal pruritusGastrointestinal disorders0/161/15
ConstipationGastrointestinal disorders0/161/15
NauseaGastrointestinal disorders0/161/15
ProctitisGastrointestinal disorders0/161/15

Baseline characteristics

Safety population: Safety population consisted of all randomised subjects who received at least one dose of study medication. Subjects were allocated to the treatment they actually received.

Age, Continuous
Age, Continuous(years)BrachytherapyBrachytherapy + Triptorelin 22.5 mgTotal
Median67.50 (59.0 to 76.0)70.00 (58.0 to 76.0)68.00 (58.0 to 76.0)
Sex: Female, Male
Sex: Female, Male(Participants)BrachytherapyBrachytherapy + Triptorelin 22.5 mgTotal
Female000
Male161531
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)BrachytherapyBrachytherapy + Triptorelin 22.5 mgTotal
Caucasian/White161531
Region of Enrollment
Region of Enrollment(Participants)BrachytherapyBrachytherapy + Triptorelin 22.5 mgTotal
Spain161531
08

Study locations

11 sites
  • Fundación IMOR
    Barcelona, Spain
  • H. de la Santa Creu i Sant Pau
    Barcelona, Spain
  • ICO Institut Català d'Oncologia-Hospitalet
    Hospitalet de Llobregat, Spain
  • H. Ramón y Cajal
    Madrid, Spain
  • H. Sanchinarro
    Madrid, Spain
  • H. Carlos Haya
    Málaga, Spain
  • Complejo Hospitalario de Navarra
    Pamplona, Spain
  • Instituto Oncológico
    San Sebastián, Spain
  • H. Universitario Marqués de Valdecilla
    Santander, Spain
  • IVO Instituto Valenciano de Oncología
    Valencia, Spain
  • H. Do Meixoeiro
    Vigo, Spain
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2017, 2 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2011
First posted
Jun 15, 2011
Start
Nov 2011
Primary completionActual
Dec 2014
CompletionActual
Dec 2014
Results first posted
Feb 23, 2017
Last update
Sep 18, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01374087
Lead sponsor
Ipsen
Responsible party
Sponsor
First posted
Jun 15, 2011
Start date
Nov 2011
Primary completion
Dec 2014
Completion
Dec 2014
Results posted
Feb 23, 2017
Last update
Sep 18, 2019

Study contacts

Ipsen Medical Director
study director · Ipsen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Triptorelin

Start the discussion